Methazolamide
Neptazane (methazolamide) is a small molecule pharmaceutical. Methazolamide was first approved as Neptazane on 1982-01-01. It is used to treat angle-closure glaucoma and open-angle glaucoma in the USA. The pharmaceutical is active against carbonic anhydrase 7. In addition, it is known to target carbonic anhydrase 12, carbonic anhydrase 1, carbonic anhydrase 14, and carbonic anhydrase 4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
eye diseases | D005128 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methazolamide
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
NEPTAZANE | Lederle Laboratories | N-011721 DISCN | 1982-01-01 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
methazolamide | ANDA | 2022-12-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
angle-closure glaucoma | — | D015812 | — |
open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | METHAZOLAMIDE |
INN | methazolamide |
Description | Methazolamide is a member of thiadiazoles and a sulfonamide. |
Classification | Small molecule |
Drug class | carbonic anhydrase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C |
Target
Alternate
CA12
CA12
CA1
CA1
CA14
CA14
CA4
CA4
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 922 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more